Clinical Trials Logo

Antithrombin III Deficiency clinical trials

View clinical trials related to Antithrombin III Deficiency.

Filter by:

NCT ID: NCT01547728 Terminated - Clinical trials for Thrombophilia Due to Acquired Antithrombin III Deficiency

Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery

Start date: February 2012
Phase: Phase 4
Study type: Interventional

The objective of this study is to prospectively evaluate the response of recombinant antithrombin (rAT) (ATRYN) in patients who are heparin resistant and are scheduled to undergo cardiac surgery.

NCT ID: NCT00938288 Completed - Clinical trials for Congenital Antithrombin Deficiency

A Study of KW-3357 in Congenital Antithrombin Deficiency

Start date: April 2009
Phase: Phase 1
Study type: Interventional

The aim of this study is to determine the pharmacokinetics, safety and tolerability of KW-3357 in asymptomatic subjects with congenital antithrombin deficiency.

NCT ID: NCT00823082 Completed - Clinical trials for Coronary Artery Bypass

Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass

Start date: May 2009
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to study the effects of preoperative antithrombin supplementation in patients undergoing cardiac surgery with cardiopulmonary bypass in order to maintain antithrombin levels in a range greater than 58% and, eventually, to decrease negative clinical outcomes during the ICU stay.

NCT ID: NCT00319228 Active, not recruiting - Clinical trials for Antithrombin III Deficiency

Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate

Start date: January 2006
Phase: Phase 2/Phase 3
Study type: Interventional

To assess the safety, pharmacokinetics and efficacy of a plasma-derived AT-III concentrate in the treatment of subjects with congenital AT-III deficiency.

NCT ID: NCT00110513 Completed - Clinical trials for Antithrombin III Deficiency

Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery

Start date: April 2005
Phase: Phase 3
Study type: Interventional

Patients with hereditary antithrombin deficiency are at increased risk of venous thrombosis and pulmonary embolism, particularly during certain high risk procedures. The trial focused on patients with confirmed hereditary antithrombin deficiency who were undergoing a surgical procedure or induced/spontaneous labor and delivery, and/or caesarean section. The study assessed the incidence of thromboembolic events following prophylactic intravenous administration of recombinant human antithrombin (rhAT) to patients with hereditary antithrombin (AT) deficiency in situations usually associated with a high risk for thromboembolic events.

NCT ID: NCT00056550 Completed - Clinical trials for Antithrombin Deficiency, Congenital

Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.

rhAT
Start date: December 2002
Phase: Phase 3
Study type: Interventional

Patients with hereditary antithrombin (AT) deficiency are at increased risk of venous thrombosis and pulmonary embolism, particularly during certain high risk procedures. The trial is focusing on patients with confirmed hereditary antithrombin deficiency who are undergoing a surgical procedure or induced/spontaneous labor and delivery. The study will test the safety and efficacy of recombinant human antithrombin (rhAT) by infusing rhAT prior to, during and following the period of risk or surgical procedure.